Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab

QR Code

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab

Abstract Although several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological f...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Kiyoshi Minohara, Takuma Matoba, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Kazuhiro Nakai, Sho Iwaki, Wataru Hojo, Ayano Matsumura, Shinya Ozaki, Taijiro Ozawa, Ikuma Harata, Nobukazu Tanaka, Shinichiro Maseki, Hiroshi Tsuge, Sae Imaizumi, Shoji Mitsuya, Kazuho Moribe, Shinichi Esaki, Shinichi Iwasaki
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2021
Sujets:	Medicine R Science Q
Accès en ligne:	https://doaj.org/article/83aafb03d05a4f159e72936107a43a7e
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
par: Nobukazu Fujimoto, et autres
Publié: (2021)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
par: Alexander N Shoushtari, et autres
Publié: (2021)

Nivolumab-Induced Exocrine Pancreatic Insufficiency
par: Boudewijn Sweep, et autres
Publié: (2021)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
par: Katsuhiro Yoshimura, MD, PhD, et autres
Publié: (2021)

Use of nivolumab for colon cancer with Lynch syndrome
par: G. A. Khakimov, et autres
Publié: (2020)

Nivolumab-associated DRESS in a genetic susceptible individual
par: Qian Li, et autres
Publié: (2021)

IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses
par: Taylor A. Harper, et autres
Publié: (2021)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
par: Shuguang Tan, et autres
Publié: (2017)

Complete regression of metastatic malignant melanoma endoscopically after nivolumab administration
par: Dae Gon Ryu, et autres
Publié: (2021)

Autoimmune hemolytic anemia during long‐term administration of nivolumab for metastatic melanoma
par: Koji Nakajima, et autres
Publié: (2021)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
par: Pramod Savarapu, et autres
Publié: (2021)

Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
par: Ryusuke Murakami, et autres
Publié: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
par: Zago G, et autres
Publié: (2016)

THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
par: Veysel GOK, et autres
Publié: (2021)

Maculopapular erythema caused by previously used chemotherapy drugs after nivolumab treatment for malignant mesothelioma
par: Junko Kanai, et autres
Publié: (2021)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
par: Tian Zhang, et autres
Publié: (2021)

A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy
par: Keisuke Minami, et autres
Publié: (2021)

Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer
par: Sarah Maryon Hayes, et autres
Publié: (2021)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
par: Romualdo Barroso-Sousa, et autres
Publié: (2021)

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
par: David Goldstein, et autres
Publié: (2021)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
par: Hiroto Yoneda, et autres
Publié: (2021)

Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma
par: Hiroe Tada, et autres
Publié: (2020)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
par: Matthew D. Tucker, et autres
Publié: (2021)

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
par: Toshiki Kijima, et autres
Publié: (2021)

Editorial: Integrated Quantum Photonics
par: Shinichi Saito
Publié: (2021)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
par: Huo Geng-wei, et autres
Publié: (2021)

Correction: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
Publié: (2021)

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
par: Ammar Haikal, et autres
Publié: (2018)

Los cinco rangos del maestro Zen Tosan : análisis estructural del despertar /
par: Shinichi Hisamatsu, Hôseki
Publié: (2011)

Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
par: Izabela Chmielewska, et autres
Publié: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
par: Rosaria De Filippi, et autres
Publié: (2021)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
par: Shahneen Sandhu, et autres
Publié: (2021)

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
par: Fabio Guolo, et autres
Publié: (2021)

Breeding biology and variable mating system of a population of introduced dunnocks (Prunella modularis) in New Zealand.
par: Eduardo S A Santos, et autres
Publié: (2013)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
par: Toshiki Ogiwara, et autres
Publié: (2021)

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
par: Koji Iinuma, et autres
Publié: (2021)

Minimum effective volume of ropivacaine for ultrasound-guided supra-inguinal fascia iliaca compartment block
par: Kumiko Yamada, et autres
Publié: (2020)

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
par: Morten Fink, et autres
Publié: (2021)

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
par: Kenji Maeda, et autres
Publié: (2021)

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
par: Wen Dong, et autres
Publié: (2021)